Literature DB >> 15623263

COX-2 inhibitor use after Vioxx: careful balance or end of the rope?

A Mark Fendrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15623263

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN： 1088-0224            Impact factor:   2.229


× No keyword cloud information.
  4 in total

1.  Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial.

Authors:  Jay L Goldstein; James Aisenberg; Salam F Zakko; Manuela F Berger; William E Dodge
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

2.  Vioxx(R): What should we tell our patients?

Authors:  Claire Johnson
Journal:  J Chiropr Med       Date:  2004

3.  Current state of therapy for pain and inflammation.

Authors:  Steven B Abramson; Arthur L Weaver
Journal:  Arthritis Res Ther       Date:  2005-09-15       Impact factor: 5.156

Review 4.  Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.

Authors:  James M Scheiman; A Mark Fendrick
Journal:  Arthritis Res Ther       Date:  2005-09-15       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.